Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
8
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
8
×
detroit blog main
detroit top stories
indiana blog main
8
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
clinical trials
startups
astrazeneca
eli lilly
alzheimer's disease
cancer immunotherapy
deals
fda
gilead sciences
merck
multiple myeloma
What
bio
roundup
drug
companies
conference
week
acquisitions
annual
ceo
daniel
debut
gilead
moves
nash
news
o’day
sciences
abbvie’s
alzheimer’s
american
announced
approval
approved
ash
assessed
attention
barbecuing
biggest
biogen’s
biopharmaceutical
biotech
black
blood
borne
build
buy
camping
cancers
cardiologist
center
Language
unset
Current search:
abbvie
×
cancer
×
" indiana blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More